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INTRODUCTION 
Self-nano-emulsifying drug delivery systems (SNEDDS) 
are defined as anhydrous homogenous liquid mixtures 
consisting of oil, surfactant, drug and co-emulsifier or 
solubiliser, which spontaneously form an oil-in-water 
nanoemulsion (NE) of approximately 200nm or less in 
size upon dilution with water, under gentle stirring.
[1]
 
 
Desai et al.
[1]
 reported that SNEDDS have potential to 
improve oral bioavailability and therapeutic efficacy of 
hydrophobic drugs via several mechanisms. 
 Improving solubility of hydrophobic drugs. 
 Improving permeability/transport for poorly 
permeable drugs. 
 Modulating biodistribution and drug disposition. 
 Preventing degradation of drugs in the physiological 
milieu. 
 Enabling targeted delivery of the drugs to the site of 
action. 
 
A NE improved the oral bioavailability, and CNS 
delivery of saquinavir
[2]
 enhanced dissolution of 
griseofulvin
[3]
 and improved the bioavailability of the 
alkaloid huperzine by lymphatic uptake.
[4]
 The authors 
concluded that the nano-size of these formulations was 
responsible for the enhancement of drug dissolution and 
absorption, owing to the large surface area.
[1]
 The 
lipophilic nature of these systems also facilitates delivery 
of drugs into difficult to penetrate tissues such as the 
central nervous system. However, such systems are 
subject to oxidation of the vegetable oils, which may 
raise safety issues. 
 
Desai et al.
[1]
 compared high- and low energy 
emulsification methods. High-energy methods require 
sophisticated equipment and extensive energy input 
which is associated with increased cost. This is 
significant in the pharmaceutical industry, leading 
researchers to focus on low-energy emulsification 
methods.
[1] 
 
The Biopharmaceutics Classification System
[5]
 (BCS) is 
a scientific framework for classifying drug substances 
based on their aqueous solubility and intestinal 
permeability. There three major factors that influence the 
rate and extent of drug absorption from immediate 
release solid oral dosage forms; dissolution, solubility 
and intestinal permeability. The BCS classified the 
immediate release solid oral formulations into Class 1: 
High Solubility – High Permeability, Class 2: Low 
Solubility – High Permeability, Class 3: High Solubility 
– Low Permeability and Class 4: Low Solubility – Low 
Permeability (FDA, Biopharmaceutics Classification 
System, 22/12/2017). Compounds in BCS class II, with a 
log P ranging 2-3 can be improved in solubility and 
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Self-nano-emulsifying drugs delivery systems present an effective drug delivery system for the formulation of a 
hydrophobic drug with poor water-solubility. Gliclazide is practically insoluble in water and is amenable for self-
nano-emulsifying drug delivery. This study aimed to develop a formulation of gliclazide using Cremophor RH 40 
and Tween 20 with capryol 90 as oil vehicle. A solubility study, particle size analysis and ternary phase diagram 
were developed to select the optimal formulation to take forward to stability testing. Accelerated physical stability 
and self-emulsification studies were performed. They were also compared for globule size, transmittance, 
polydispersity index and zeta potential. The solubility was greatest in Capryol 90 64.86 mg/mL, Cremophor RH 
40 44.98 mg/mL, PEG 400 105.66 mg/mL, and Tween 20 86.83 mg/mL. The construction of the ternary phase 
diagram in the formulation using cremophor 40 as surfactant has good characteristics and wide area in nano-
emulsifying formation than Tween 20. Gliclazide can be formulated and exhibits good stability in a self-nano-
emulsifying drug delivery system. 
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bioavailability using self-lipid formulations.
[6]
 Gliclazide 
is a sulfonylurea derivative, widely used in diabetes 
treatment around the world, which is only partially 
soluble in water. The absorption of gliclazide is 
influenced by the size of the particle.
[7]
 The 
reformulation of the related sulphonylurea glipizide, to 
enhance solubility and dissolution, has been proposed.
[8] 
(A self-emulsifying gliclazide was formulated in the 
micron size range
[9]
, but to date no attempt to use a nano-
size delivery system for this medication has been 
identified. 
 
Nanoparticles as drug delivery systems 
Wilczewska et al.
[10] 
reviewed nanoparticles as a drug 
delivery system (DDS), specifically nanocarriers, and 
their interactions with drugs. The paper suggested that 
using nanoparticles as DDS can overcome some of the 
conventional limitations of drugs, such as limited 
effectiveness due to poor distribution and lack of 
receptor sensitivity.
[10]
 Their review found that 
nanocarriers with optimized physicochemical and 
biological properties are taken up by cells more readily 
than larger molecules, meaning they can be used as 
delivery tools for currently available bioactive 
compounds.
[10] 
 
The article explains that the method of incorporating the 
drug with the nanocarrier, and the strategy of its 
targeting, are important considerations. A drug may be 
absorbed, or covalently attached to the nanocarriers’ 
surface, or it can be encapsulated into it. Once the drug 
nanocarrier conjugate reaches the tissues, the therapeutic 
agent is released. Controlled release may be achieved 
through changes in temperature, pH, and osmolality or 
via enzymatic activity.
[10] 
The authors concluded that 
nanocarriers as DDS are designed to improve the 
pharmacological and therapeutic properties of 
conventional drugs, and that the incorporation of drug 
molecules into nanocarriers can protect a drug against 
degradation, whilst in addition, offering possibilities of 
targeting and control of release characteristics.
[10]
 In 
comparison with traditional formulations, nanocarrier-
drug conjugates are more effective and selective. They 
have the potential to reduce the toxicity and other 
adverse side effects in normal tissues by accumulating 
the drug at target sites, resulting in a lower dosage 
requirement. Conversely, drawbacks of nanoparticle-
based targeting systems include; process scale-up issues, 
low drug loading capacity, low loading efficiency and 
poor ability to control the size distribution of carriers.
[10]
 
 
Martin et al.
[11]
 investigated the use of nano self-
emulsifying systems for managing poorly water-soluble 
drugs. The study highlights the confusion on 
differentiating between self-micro-emulsifying drug 
delivery systems (SMEDDS) and self-nano-emulsifying 
drug delivery systems (SNEDDS). The author defines a 
microemulsion to be a thermodynamically stable fluid 
mixture of water, oil and surfactants. This definition 
differentiates microemulsions from NE, which may only 
be kinetically stable. It also highlights the importance of 
differentiating between SMEDDS and SNEDDS as it 
may have a biopharmaceutical relevance. The study 
found that theoretical considerations indicated that 
particle size alone is often not sufficient to assign 
categories; and polydispersity must be considered. They 
proposed stability categories to differentiate stable 
swollen micelles and consequently microemulsions from 
NE.
[11]
 
 
The study of Bhattacharya and Prajapati
[12]
, investigated 
the formulation approach for self-emulsifying drug 
delivery systems. They state that self-emulsifying drug 
delivery systems (SEDDS) offer a promising new 
approach. The authors highlight the value of SEDDS 
because 40% of new drug candidates exhibit poor 
aqueous solubility and nearly 50% are highly lipophilic 
in nature. The study found that surfactants having 
hydrophilic-lipophilic balance (HLB)>12 makes good 
candidates for SEDDS. They also highlighted the 
importance of using suitable excipients
12
. The table 
below outlines the types of oils used in marketed SEDDS 
(table 1). 
 
 
Table 1: The types of oils used in marketed products based upon SEDD’s (data from12). 
Type of Oil Marketed Product Medication 
Corn Oil Depakene™ Capsules Valproic Acid 
Olive Oil Sandimmune™ Oral Solution Cyclosporine 
Sesame Oil Marinol™ Soft Gelatin Capsule Dronabinol 
Soya Bean Oil Accutane™ Soft Gelatin Capsule Isotretinoin 
Peanut Oil Prometrium™ Soft Gelatin Capsule Progesterone 
Hydrogenated Soya Bean Oil Accutane™ Soft Gelatin Capsule Isotretinoin 
Bees Wax Vesanoid™Soft Gelatin Capsule Tretinoin 
 
Bhattacharya and Prajapati
[12]
 concluded that self-
emulsifying drug delivery systems offer a promising 
approach towards projecting future generations of dosage 
formulations. Many studies reveal that the physical 
stability of the drug is enhanced when an SEDDS 
formulation is used. Most importantly, BCS 2 and 4 
drugs have a wider application in SEDDS formulations. 
SEDDS are mainly prepared in liquid dosage form, but 
due to stability in solid SEDDS forms, more research is 
projected in this direction.
[12]
 
 
The aim of this study was to pilot a formulation of 
gliclazide in a self nano-emulsifying delivery system that 
is physico-chemically stable. 
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METHOD 
The project was conducted as part of a student exchange 
experience between the University of Wolverhampton 
UK and Universitas Islam Indonesia at the 
nanotechnology laboratory by a UK student supervised 
by local Faculty. 
 
Gliclazide was a purchased from a local pharmaceutical 
company in Indonesia (origin, Zhejiang Jiuzhou 
Pharmaceutical Co. Ltd., Taizhou City, China), Capryol 
90 (Gattefose, Saint-Priest, France), Chremopore RH 40 
(Sigma-Aldrich, St Louis, MI, USA) Tween 20 and PEG 
400 Kao, Tokyo, Japan), Na2HPO2.2H2O, KH2PO4, HCl 
37% analytical grade (Merck, Darmstadt, Germany), 
Methanol (HPLC Grade, J.T Baker, Fair Lawn, USA) 
 
Chromatographic Analysis 
The assay of gliclazide used a high-pressure liquid 
chromatography method (Waters e2695 with UV-Vis 
24890)(Waters Corporation, Milford MI, USA). Sunfire 
C18 Column (250 mm X 4,6 mm, 0.5 µm)(Waters 
Corporation, Milford MI, USA) was utilized to obtain 
separation with a mobile phase of methanol and 
phosphate buffer pH 3 (70:10), 1 mL/min flow rate and 
wavelength 229 nm UV detection. 
 
Solubility Test for Excipient 
To test the solubility of gliclazide in different excipient 
oils, surfactant and co-surfactant, an excess amount of 
gliclazide was added to each of the Eppendorf™ tubes 
containing 1 ml of test substance. The potential 
excipients investigated were Capryol 90 (oil), 
Chremopor RH (Surfactant) and PEG 400 (Co-
Surfactant). The mixture was vortexed on vortex mixer 
for 5 min to facilitate proper mixing and dissolution of 
gliclazide in that excipient. The mixtures were then 
allowed to equilibrate at 30°C for 72 hours in shaker 
(Memmert WNB29 with Shaker SV2945), (Memmert, 
Schwabach, Germany). The samples then centrifuged at 
10,000 rpm (Hettich Mikro185), (Hettich, Pocklington, 
UK) for 13 min to separate the undissolved drug. 
Aliquots of supernatant were suitable diluted and the 
gliclazide present in each excipient quantified by HPLC. 
Standards were prepared by dissolving weighed aliquots 
of gliclazide in each diluent. 
 
Construction of ternary phase diagrams 
The ternary phase diagram was prepared from the 
mixture of selected various concentration of oil, 
surfactant and co-surfactant mixture with sonication 
(Biologics, Inc 300VT), (Biologics, Woburn, MA, USA). 
Ternary phase diagrams of oil, surfactant and co-
surfactant were plotted; each of them representing an 
apex of the triangle using Triplot 4.1.2 software 
(Loughborough University, Loughborough, UK). All 
compositions were examined for NE formation after 
diluting each of the mixtures to 250 ml with double-
distilled water. Thereafter, transmittance of the resulting 
dispersions were determined by using UV/Visible 
spectrophotometer 650 nm (Hitachi U-2900)(Hitachi, 
Tokyo, Japan), and globule size, polydisperse index 
(PDI) and zeta potential, determined by using particle 
size analyser (Horiba SZ-100), (Horiba, Fukuoka, 
Japan). The table of the ternary diagram mixture was 
used to select formulae with various concentrations (% 
v/v) of capryol 90, cremophor RH 40, tween 80 and PEG 
400 to evaluate. The Capryol 90 solution had a high 
range concentration providing a suitable loading capacity 
to act as a vehicle for gliclazide (Table 2). 
 
 
Table 2: Ternary diagram mixture of selected formula with various concentration. 
Material Low concentration (% ) High concentration (%) 
Capryol 90 40 65 
Cremopor RH 40 5 55 
Tween 20 5 55 
PEG 400 5 55 
 
Centrifugation test 
Gliclazide SNEDDS were diluted 100 times using Water 
for Injections, then centrifuged at 3,500 rpm for 30 
minutes. It was then observed visually to check the phase 
separation. 
 
Heating-cooling cycle test 
The heating-cooling cycle test was conducted for six 
cycles across a temperature range from 4
o
C and 40
o
C 
with storage of the formula for not less than 48 hours. 
The formula would need to be stable for this test. The 
formula was centrifugated to 3,500 rpm for 15 minutes 
and then it was observed visually to check the phase 
separation. 
 
 
 
Freeze-thaw cycle test 
The freeze-thaw cycle test was conducted with six cycles 
across a temperature range from -20
o
C and 25
o
C with 
storage of the formula for not less than 48 hours. The 
formula must be stable at this temperature. The formula 
was centrifuged visually observed to check the phase 
separation. 
 
Endurance test 
The formula was diluted with the dilutions of 25, 50, 
100, and 250 times with water for injections. Then, the 
change in transmittance, polydispersity index (PDI), and 
particle size of the formula was evaluated.
[13]
 
 
Accelerated storage stability test 
The accelerated storage test, which was conducted for 1 
month with the storage condition of 40
o
C±2
o
C/ 75% 
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RH±5% RH. Then, the change of % transmittance, 
polydispersity index (PDI), and particle size of the 
formula was evaluated at weeks 0, 1, 2, 3, and 4.
[14]
 
 
HPLC Method Development and Validation 
a. Preparation in Phosphate buffer pH 3 
Phosphate buffered solutions of gliclazide were prepared 
by dissolving 0,68 gram KH2PO4 in a 500 ml volumetric 
flask and Phosporic Acid 85% (An aliquot 0,613 ml of 
this solution was diluted with double-distilled water in a 
10 ml volumetric flask).A sample of 0.7 ml from these 
solutions in a 500 ml volumetric flask with KH2PO4, the 
volume was made up to the mark with double-distilled 
water to achieve the pH 3. 
 
b. Preparation Standard Stock Solutions 
Standard stock solutions of gliclazide were prepared by 
dissolving 10 mg in 100 mL methanol to obtain 
concentration 100 μg/mL. 
 
c. Determination of λmax 
An accurately weighed quantity of gliclazide (10 mg) 
each were transferred in 100 ml volumetric flask, 
dissolved in sufficient quantity of methanol. The volume 
was made up to the mark with methanol to achieve the 
concentration 100 μg/ml. An aliquot (1 ml) of this 
solution was diluted with methanol in a 10 ml volumetric 
flask up to mark to achieve a final concentration of 
10μg/ml. The standard solution of gliclazide was scanned 
in the range of 200-400 nm using HPLC and was 
recorded to determine the λmax of the drugs. The study of 
spectrum revealed that gliclazide showed a well-defined 
λ
max 
at 229 nm. 
 
d. Linearity and Range 
As per ICH guidelines, the linearity of an analytical 
procedure is its ability (within a given range) to obtain 
test results which are directly proportional to the 
concentration (amount) of analyte in the sample. 
Linearity study for the proposed method was established 
by least-square linear regression analysis. Sample 
solutions of gliclazide were prepared in the concentration 
range of 10μg/ml, 20μg/ml, 30μg/ml, 40μg/ml, and 
50μg/ml by transferring appropriate volume of stock 
solution to a 10 ml of volumetric flask and making up the 
volume with methanol. All dilutions were scanned in 
λ
max 
at 229 nm. 
 
RESULTS 
Solubility Test for Excipient 
A solubility test was conducted to select suitable 
excipients for the SNEDD formulation. The criteria for 
selection of the excipients were:(1) the formulation 
should be safe and biocompatible using small amount 
surfactant and co-surfactant to produce the NE. (2) the 
compositions should develop a large NE area formation 
in the ternary phase diagram. (3) It must have a high 
drug loading (4) The SNEDDS formulation should 
provide a small and homogeneous emulsion droplet 
size.
[15]
 (The solubility of gliclazide in excipient was 
determined by HPLC analysis in surfactant, co-surfactant 
and oil. The solubility of gliclazide in the co-surfactant 
was highest in PEG 400 (Table 3). 
 
 
 
 
 
 
 
 
 
Table 1: The solubility of gliclazide in different excipient including oil, surfactant and co-surfactant. Data are 
represented by mean value ± SD (n=6) 
Vehicles Solubility (mg/mL) Mean ± SD 
Capryol 90 Oil 64.857 ±15.378 
Surfactant - Cremophor RH 40 44.975 ±2.513 
Tween 20 Co-surfactant 86.834 ±0.455 
PEG 400 105.660 ±0.171 
 
Gliclazide in PEG 400 had the highest solubility 105.66 
mg/mL. The solubility each excipient of SNEDDs 
formulation impacts the formulation because lower 
surface tension can produce smaller globules in the 
emulsifying formation. The free energy of a regular 
emulsion formation is a direct function of the energy 
required to develop a new surface between the oli and 
water phase, the two-phases contribute to separate time-
dependent decreases in the interfacial area and thus the 
free energy of the system, and will develop a droplet of 
an emulsion stabilized by the emulsifying agent. 
Spontaneous emulsification occurs due to lower free 
energy.
[16]
 Self-emulsification results when the entropy 
favouring dispersion is greater than energy needed to 
increase the surface area of the dispersion.
[17]
 
 
Ternary Phase Diagram 
Tables 4-13 show the results for the gliclazide 
formulation into a NE using different surfactants in 
different oil: surfactant ratio combinations. The selection 
of co-surfactant of the SNEDDS formulations can be 
evaluated from the size of globule formation, % 
transmittance and polydispersity index. The criteria 
sought are size below 200nm, % transmittance 70-100% 
and Polydispersity index (P.I) below 0.7. The formation 
diagram constructed with surfactant cremophor RH40 
showed a better area in NE formation than using tween 
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20 (Table 3). The formulation containing cremophor 
RH40 can produce NE with capryol 90 as oil up to 50% 
in those proportions. On the other hand using tween 80 
as surfactant can develop a NE with oils ratio until 65% 
but lower % transmittance. 
 
 
Table 2: Oil: Surfactant mix (Smix) (40:60). 
No. 
Capryol 
90 
Cremophor 
RH 
PEG 
400 
Size (nm) 
% 
Transmittance 
P.I. 
1 40 5 55 336.90 ± 1.40 5.570 ±0.009 0.534 ± 0.038 
2 40 10 50 372.90 ± 4.90 3.108 ±0.004 0.659 ± 0.041 
3 40 15 45 200.90 ±4.10 1.718 ±0.001 0.473 ± 0.040 
4 40 20 40 117.10 ± 0.50 31.183 ±0.065 0.393 ± 0.029 
5 40 25 35 85.80 ± 0.70 70.780 ±0.042 0.400 ± 0.001 
6 40 30 30 54.50 ± 0.20 83.593 ±0.042 0.389 ± 0.025 
7 40 35 25 37.50 ± 0.60 91.475 ±0.029 0.406 ± 0.022 
8 40 40 20 77.40 ±2.00 93.670 ± 0.073 0.535 ± 0.001 
9 40 45 15 119.70 ± 0.20 89.504 ± 0.045 0.668 ± 0.029 
10 40 50 10 170.30 ± 0.50 87.312 ±0.008 0.698 ± 0.011 
11 40 55 5 184.60 ± 1.30 84.348 ±0.016 0.627 ± 0.040 
 
Table 3: Oil: Smix (45:55). 
No. 
Capryol 
90 
Cremophor 
RH 
PEG 
400 
Size (nm) 
% 
Transmittance 
P.I. 
1 45 5 50 351.10 ±26.00 8.931 ±0.018 0.470 ±0.780 
2 45 10 45 372.90 ± 4.90 3.231 ±0.002 0.659 ± 0.041 
3 45 15 40 212.50 ± 1.80 1.096 ± 0.000 0.383 ± 0.006 
4 45 20 35 179.50 ± 13.20 21.173 ±0.006 0.404 ± 0.053 
5 45 25 30 70.20 ± 0.50 69.123 ± 0.061 0.438 ± 0.023 
6 45 30 25 43.70 ± 0.20 89.130 ± 4.078 0.352 ± 0.039 
7 45 35 20 45.60 ± 0.30 86.505 ± 0.005 0.439 ± 0.033 
 
Table 4: Oil: Smix (50:50) 
No. Capryol 90 Cremophor RH PEG 400 Size (nm) % Transmittance P.I. 
1 50 45 5 35.60 ± 1.20 87.297 ±0.188 0.546 ± 0.024 
2 50 40 10 60.60 ± 1.40 82.974 ±0.012 0.422 ± 0.019 
3 50 35 15 75.10 ± 0.50 70.520 ±0.039 0.447 ± 0.036 
4 50 30 20 89.60 ± 0.40 35.132 ±0.021 0.387 ± 0.010 
5 50 25 25 186.00 ± 0.50 0.880 ± 0.000 0.420 ± 0.037 
6 50 20 30 262.70 ± 2.70 1.122 ± 0.000 0.690 ± 0.014 
7 50 15 35 324.30 ±12.70 0.937 ± 0.000 0.711 ± 0.031 
 
Table 5: Oil: Smix (60:40) 
No. 
Capryol 
90 
Cremophor 
RH 
PEG 400 Size (nm) % Transmittance P.I. 
1 60 35 5 2914.90 ± 919.30 7.301 ±0.045 2.996 ± 0.628 
2 60 30 10 2325.30 ± 163.60 4.899 ±0.148 1.463 ± 0.298 
3 60 25 15 n.d 1.332 ±0.002 n.d 
4 60 20 20 n.d 34.244 ±0.033 n.d 
5 60 15 25 n.d 58.632 ±5.680 n.d 
6 60 10 30 n.d 61.133 ±0.006 n.d 
7 60 5 35 n.d 54.666 ±0.033 n.d 
 
Table 6: Oil: Smix (65:35) 
No. Capryol 90 Cremophor RH PEG 400 Size (nm) % Transmittance P.I. 
1 65 2,5 32,5 n.d 7.772 ±0.001 n.d 
2 65 5 30 n.d 1.227 ± 0.004 n.d 
3 65 10 25 n.d 0.692 ±0.001 n.d 
4 65 15 20 n.d 0.404 ± 0.001 n.d 
5 65 20 15 n.d 7.304 ±0.000 n.d 
6 65 25 10 n.d 19.711 ± 0.001 n.d 
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Table 7: Oil: Smix (40:60). 
No. Capryol 90 Tween 20 PEG 400 Size (nm) % Transmittance P.I. 
1 40 5 55 n.d 7.376 ±0.044 n.d 
2 40 10 50 n.d 3.290 ±0.002 n.d 
3 40 15 45 n.d 2.901 ±0.003 n.d 
4 40 20 40 n.d 2.382 ±0.002 n.d 
5 40 25 35 264.30 ± 29.00 1.405 ±0.000 0.473 ± 0.018 
6 40 30 30 188.60 ± 3.30 1.072 ±0.001 0.356 ± 0.031 
7 40 35 25 240.80 ± 13.00 1.265 ±0.000 0.488 ± 0.059 
8 40 40 20 386.90 ± 140.80 2.425 ± 0.002 0.580 ± 0.174 
9 40 45 15 206.60 ± 1.30 3.107 ±0.000 0.403 ± 0.047 
10 40 50 10 235.40 ± 6.40 3.137 ±0.002 0.540 ± 0.086 
11 40 55 5 371.60 ± 112.40 2.386 ± 0.002 0.479 ± 0.108 
 
Table 8: Oil: Smix (45:55). 
No. Capryol 90 Tween 20 PEG 400 Size (nm) % Transmittance P.I. 
1 45 5 50 4729.00 ± 8.60 2.020 ±0.001 7.535 ± 1.722 
2 45 10 45 n.d 2.821 ±0.006 n.d 
3 45 15 40 404.10 ± 45.00 3.199 ±0.002 3.090 ± 0.148 
4 45 20 35 97.80 ± 0.00 3.226 ±0.005 1.369 ± 0.000 
5 45 25 30 145.60 ± 4.80 1.504 ±0.001 0.386 ± 0.224 
6 45 30 25 186.70 ± 3.00 1.431 ± 0.001 0.514 ± 0.125 
7 45 35 20 175.60 ±0.00 1.098 ± 0.001 0.853 ± 0.000 
 
Table 9: Oil: Smix (50:50). 
No. Capryol 90 Tween 20 PEG 400 Size (nm) % Transmittance P.I. 
1 50 5 45 158.90 ±34.90 11.338 ±0.073 0.314 ±0.073 
2 50 10 40 187.60 ± 5.20 6.258 ±0.011 0.360 ± 0.183 
3 50 15 35 1637.50 ± 310.00 6.605 ±0.032 0.702 ± 0.002 
4 50 20 30 229.00 ± 0.00 4.884 ± 0.014 0.427 ± 0.000 
5 50 25 25 187.80 ± 5.50 2.522 ± 0.002 0.412 ± 0.045 
6 50 30 20 314.80 ±6.60 1.678 ± 0.002 0.485 ± 0.078 
7 50 35 15 467.40 ± 41.50 1.344 ±0.001 0.510 ± 0.098 
 
Table 10: Oil: Smix (60:40). 
No. Capryol 90 Tween 20 PEG 400 Size (nm) % Transmittance P.I. 
1 60 5 35 2723.00 ± 0.00 3.407 ±0.029 1.472 ± 0.000 
2 60 10 30 n.d 3.168 ±0.014 n.d 
3 60 15 25 n.d 1.419 ±0.007 n.d 
4 60 20 20 838.80 ± 14.20 1.430 ±0.004 5.678 ± 6.579 
5 60 25 15 842.50 ± 1013.80 1.843 ±0.000 1.250 ± 0.540 
6 60 30 10 113.10 ± 26.40 1.476 ±0.002 0.777 ± 0.607 
7 60 35 5 184.30 ± 12.50 1.504 ±0.001 0.591 ± 0.145 
 
Table 11: Oil: Smix (65:35). 
No. Capryol 90 Tween 20 PEG 400 Size (nm) % Transmittance P.I. 
1 65 2,5 32,5 4669.90 ± 362.10 4.141 ±0.019 5.762 ± 1.934 
2 65 5 30 n.d 1.927 ±5.194 n.d 
3 65 10 25 n.d 2.029 ±0.003 n.d 
4 65 15 20 505.90 ± 31.60 1.619 ±0.002 5.132 ± 0.336 
5 65 20 15 465.80 ± 38.20 1.274 ±0.000 3.120 ± 0.078 
6 65 25 10 131.50 ± 5.80 1.467 ±0.001 0.524 ± 0.143 
 
From the tables above, the SNEDDS gliclazide 
formulation in various concentrations of capryol 90 using 
cremophor RH40 and PEG 400 as co-surfactant possess 
good characteristics in size formation below 200nm and 
provide the largest self-nano emulsifying region with 
high oil proportion, providing optimal loading capacity. 
 
Based on the ternary diagram area formation (Figure 1), 
the composition of surfactant, co-surfactant and oil can 
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be developed from cremophor RH 40, PEG 400 and 
Capryol 90. Surfactant cremophor RH 40 can develop 
the larger area in NE formation (system A). The largest 
area formation will produce good proportion and stability 
of NE dispersed system. 
 
 
 
Figure 1: phase diagram of system A (Capryol 90/Cremophor RH/PEG 400); system B (Capryol 90/Tween 
20/PEG 400. Blue areas represent the region of self-nanoemulsifying formation region. 
 
Formulation of Gliclazide SNEDDs 
The selected excipients for the gliclazide SNEDDs 
formulation was taken from larger ternary diagram 
region. Gliclazide was weighed and up to 40 mg added to 
Cremophor RH40 as surfactant and then sonication was 
applied to facilitate homogenization. This mix was then 
added PEG 400 as the co-surfactant and sonicated and 
finally this mix was added to Capryol 90 as the oil phase. 
The final mixture was sonicated for 2 minutes. 
 
The formulation for the stability study was prepared 
from capryol 90, cremophor RH40 and PEG 400, the 
ratio of Oils/Surfactan and Co-Surfactant (Smix) was 4:6; 
4.5:5.5 and 5:5. Based on table 14 the characteristics for 
the gliclazide have a small globul size (below 200 nm), 
Polydispersity index lower than 0.7 and % transmittance 
almost 100%, it showed this formula has characteristics;, 
clear and with a small globul size. 
 
Table 12: Formulation of SNEDDs contains 40 mg gliclazide in 2.5 mL. Data are represented by mean value ± 
SD (n=3). 
Oil:Smix 
Capryol 
90 (oil) 
Chremphor RH 
40 (surfactant) 
PEG 400 (Co-
surfactant) 
Particle 
size (nm) 
P.I 
Transmittance 
(%) 
4:6 40 30 30 55.7±1.9 0.457±0.02 99.80 
 40 35 25 55.1±1.5 0.397±0.01 99.69 
4.5:5.5 45 20 35 127,4±0,3 0,318±0,01 96,47 
 45 25 30 109,8±1 0,378±0,02 97,98 
5:5 50 30 20 87,6±0,8 0,477±0,00 98,95 
 50 25 25 122,1±2,9 0,340±0,03 97,15 
 
Centrifugation Test 
The Gliclazide SNEDDS was diluted 100 times using 
water for injections, then centrifuged at 3,500 rpm for 30 
minutes. It was then evaluated to check the phase 
separation (Table 15). The formula exhibited good 
stability against phase separation. 
 
 
Table 13: Centrifugation test for the formulation, centrifuge at 3.500 rpm for 30 minutes (n=2). 
Oil:Smix 
Capryol 
90 (oil) 
Chremphor RH 40 
(surfactant) 
PEG 400  
(Co-surfactant) 
Replication 1 Replication 2 
4:6 40 30 30 No separation No separation 
 40 35 25 No separation No separation 
4.5:5.5 45 20 35 No separation No separation 
 45 25 30 No separation No separation 
5:5 50 30 20 No separation No separation 
 50 25 25 No separation No separation 
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Heating-cooling cycle test 
The stable formulae from the centrifugation test was 
used to conduct the heating-cooling cycle test. Six cycles 
across a temperature range of 4
o
C and 40
o
C with storage 
of the formula for not less than 48 hours. The formula 
must be stable at this temperature. Then, the formula was 
centrifugated with speed of 3,500 rpm for 15 minutes. 
No phase separation occurs (Table 16). 
 
 
Table 14: Heating and cooling test provide absent phase separation during heating-cooling at the 4oC and 40oC. 
Oil:Smix 
Capryol 
90 (oil) 
Chremphor RH 
40 (surfactant) 
PEG 400 (Co-
surfactant) 
Replication 1 Replication 2 
4:6 40 30 30 No separation No separation 
 40 35 25 No separation No separation 
4.5:5.5 45 20 35 No separation No separation 
 45 25 30 No separation No separation 
5:5 50 30 20 No separation No separation 
 50 25 25 No separation No separation 
 
Freeze-thaw cycle test 
The stable formulae resulting from the heating-cooling 
cycle test was used to conduct the freeze-thaw cycle test 
that was conducted with six cycles at the temperature of -
20
o
C and 25
o
C with storage of the formula was not less 
than 48 hours. The formula must be stable at this 
temperature. Then, the formula was centrifugated with 
speed of 3,500 rpm for 15 minutes, and then it was 
observed visually to check the phase separation (Table 
17). 
 
Table 15: The Freeze-thaw cycle test for the formula in six cycles at the -20oC and 25oC, the formula have good 
stability from freeze condition. 
Oil:Smix 
Capryol 
90 (oil) 
Chremphor RH 
40 (surfactant) 
PEG 400 
 (Co-surfactant) 
Replication 1 Replication 2 
4:6 40 30 30 No separation No separation 
 40 35 25 No separation No separation 
4.5:5.5 45 20 35 Separation Separation 
 45 25 30 No separation No separation 
5:5 50 30 20 Separation Separation 
 50 25 25 No separation No separation 
 
Endurance test 
The stable formulae from the freeze-thaw cycle test was 
used to conduct the endurance test. The formula was 
diluted with the dilutions of 25, 50, 100, and 250 times 
with water for injections. Then, the change of % 
transmittance, P.I., and particle size of the formula was 
evaluated (Table 18). 
 
 
 
Table 16: Formulation endurance test. 
Oil:Smix 
Capryol 
90 
Chremphor 
RH 40 
PEG 
400 
Globul size (nm) mean ± SD (n=3) 
25 x 
dilution 
50 x 
dilution 
100 x dilution 250 x dilution 
4:6 40 30 30 113±0,9 72.9±0.7 63.7±0,4 24.3±0.3 
 40 35 25 116.5±0.3 22.5±0.3 21.6±0.2 22.3±0.5 
4.5:5.5 45 20 35 n.d n.d n.d n.d 
 45 25 30 129.4±1.3 127.7±0.5 86.4±0.4 55.2±0.3 
5:5 50 30 20 n.d n.d n.d n.d 
 50 25 25 108.5±0.3 115.4±0.2 83.4±0.4 64.8±1.3 
Oil:Smix 
Capryol 
90 
Chremphor 
RH 40 
PEG 
400 
Polidispersity Index mean ± SD (n=3) 
25 x 
dilution 
50 x 
dilution 
100 x dilution 250 x dilution 
4:6 40 30 30 0.287±0.03 0.273±0.02 0.308±0.4 0.162±0.04 
 40 35 25 0.347±0.05 0.034±0.02 0.026±0.0 0.025±0.02 
4.5:5.5 45 20 35 n.d n.d n.d n.d 
 45 25 30 0.273±0.00 0.344±0.03 0.317±0.01 0.384±0.01 
5:5 50 30 20 n.d n.d n.d n.d 
 50 25 25 0.282±0.03 0.375±0.03 0.356±0.04 0.367±0.02 
Oil:Smix Capryol Chremphor PEG % transmittance mean ± SD (n=3) 
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90 RH 40 400 25 x 
dilution 
50 x 
dilution 
100 x dilution 250 x dilution 
4:6 40 30 30 32.83±0.3 71.80±0.7 89.61±0.2 99.72 ±0.1 
 40 35 25 0.37±0.05 97.59±0.3 99.35 ±0.6 100.01 ±0.2 
4.5:5.5 45 20 35 n.d n.d n.d n.d 
 45 25 30 0.64 ±0.07 28.77±0.4 67.68±1.1 98.27 ±1.2 
5:5 50 30 20 n.d n.d n.d n.d 
 50 25 25 5.23±0.01 31.99±0.2 60.46±0,4 97.37 ±0,5 
 
Linearity and Range 
Six different concentrations (2, 4, 6, 8, 10, 12 µg/mL) 
were obtained from the stock solution and diluted with 
methanol followed by a calculation of the limit of 
regression coefficient (r), slope, and intercept. The 
regression test (Figures 2 and 3) indicated that the 
concentration series gliclazide showed 0.9998 regression 
coefficient with the equation y=18017x-1670.1. The ICH 
(International Committee on Harmonization) 
recommends that a good linearity value for the analysis 
should be more than 0.998. The obtained linearity value 
has followed the defined criteria. 
 
 
 
Figure 2: Gliclazide calibration curve with six variation concentration series gliclazide showed 0.9998 regression 
coefficient with the equation y=18017x-1670.1 
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Figure 3: Gliclazide chromatogram (A) and gliclazide in PEG 400 sample of solubility test. 
 
DISCUSSION 
This pilot study was a resource-limited student project 
which nevertheless suggests good potential for the use of 
SNEDDS as a delivery system for this widely used drug, 
using well established approaches.
[18]
 
 
The structures in NEs are much smaller than visible light 
wavelengths; so many NEs appear transparent.
[19]
 The 
average droplet size of NEs ranges from 20 to 500 nm.
[20]
 
Consequently, NEs are transparent or translucent with a 
bluish colouration.
[21]
 They are, by nature, sensitive 
systems because they are usually very fluid; at and signs 
of destabilization readily appear. Their very small 
droplet size causes a large reduction in gravity force, and 
Brownian motion may be sufficient for overcoming 
gravity.
[22] 
Brownian motion prevents sedimentation or 
creaming, thus offering increased physical stability.
[23]
 
They may have high kinetic stability because their small 
droplet size makes them stable against sedimentation and 
creaming.
[24]
 The small droplet size also prevents any 
flocculation of the droplet. 
 
Choosing the optimal formulation generally requires 
trading between optimal particle size, mean dissolution 
time, emulsification time and maximisation of drug 
release.
[18]
 Further work would be required to develop 
this into a viable delivery system. 
 
A solubility test was used to select suitable excipient in 
SNEDDS. The solubility of gliclazide in excipient was 
determined by HPLC analysis in surfactant, co-surfactant 
and oil was highest in PEG 400. It was found that for 
loading drug capacity, high oils will increase capacity of 
drug incorporated into the formulation in drug delivery 
system. The NE formulation prepared was selected for 
globule size below 200nm, transmittance percentage of 
70-100% and P.I. below 0.7. The composition of 
surfactant, co-surfactant and oil was achieved by using 
Cremophor RH 40, PEG 400 and Capryol 90 resulted in 
the largest area formation which produced stability of the 
NE disperse system. 
 
The gliclazide SNEDDs formulation has shown a good 
stability, no phase separation. 
 
The regression test indicated that the concentration series 
gliclazide showed 0.9998 regression coefficient with the 
equation y=18017x-1670.1. The ICH (International 
committee on Harmonization) recommends that a good 
linearity value for the analysis should be more than 
0.998. The obtained linearity value has followed the 
defined criteria. 
 
The solubility in Capryol 90 64.86 mg/mL, Cremophor 
RH 40 44.98 mg/mL, PEG 400 105.66 mg/mL, and 
Tween 20 86.83 mg/mL. The construction of ternary 
phase diagram in the formulation using Cremophor 40 as 
surfactant has a good characteristic and wide area in 
nano emulsifying formation than Tween 20. The 
gliclazide can be formulated and good stability in 
SNEDDs using Cremophor RH 40, PEG 400 and 
Capryol 90. 
 
CONCLUSION 
The application of a SNEDDS formulation of gliclazide 
offers the potential for improved delivery and a possible 
reduction in side effects for this very widely used agent. 
 
Benefit to practice 
When a medication is newly marketed and under patent 
protection there is little enthusiasm at that stage for 
adopting novel formulations. Advances in formulation 
science however offer opportunities to re-visit a number 
of established medicines to improve the formulations. 
Diabetes mellitus type 2 is a global epidemic that society 
is currently failing to control, and better tools may assist. 
 
Limitation 
This was a pilot project undertaken by an undergraduate 
student with limited resources and further development 
would be required. 
 
Funding: self-funded. 
 
Conflict of interest: Nil known. 
www.ejbps.com 
Morrissey et al.                                                              European Journal of Biomedical and Pharmaceutical Sciences 
 
 
 
 
ACKNOWLEDGEMENT 
The United Kingdom counterparts are very appreciative 
of the professionalism, care and hospitality that were 
provided by the Indonesian researchers during the testing 
and laboratory work period. 
 
REFERENCES 
1. Date AA, Desai N, Dixit R, Nagarsenker, M. Self-
Nanoemulsifying Drug Delivery Systems: 
Formulation Insights, Applications and Advances. 
Nanomedicine, 2010; 5(10): 1595-1616. 
DOI:10.2217/nnm.10.126. 
2. Vyas TK, Shahiwala A, Amiji MM. Improved oral 
bioavailability and brain transport of Saquinavir 
upon administration in novel nanoemulsion 
formulations. Int J Pharm, 2008; 347: 93–101 
https://doi.org/10.1016/j.ijpharm.2007.06.016. 
3. Arida AI, Al-Tabakha MM, Hamoury HA. 
Improving the high variable bioavailability of 
griseofulvin by SEDDS. Chem Pharm Bull (Tokyo), 
2007; 55(12): 1713–1719. 
4. Li F, Hu R, Wang B, Gui Y, Cheng G, Gao S, Ye L, 
Tang J. Self-microemulsifying drug delivery system 
for improving the bioavailability of huperzine A by 
lymphatic uptake. Acta Pharm Sin, 2017; 7: 353–
360. DOI: 10.1016/j.apsb.2017.02.002. 
5. Biopharmaceutics Classification System available at 
https://www.fda.gov/downloads/Drugs/GuidanceCo
mplianceRegulatoryInformation/Guidances/UCM07
0246.pdf. 
6. Jannin V, Chevrier S, Michenaud M, Dumont C, 
Belotti S, Chavant Y, Demarne F. Development of 
self emulsifying lipid formulations of BCS class II 
drugs with low to medium lipophilicity. Int J 
Pharmaceut, 2015; 495: 385–392. DOI: 
10.1016/j.ijpharm.2015.09.009. 
7. Al-Omary FAM. Gliclazide. in: Volume 42, Brittain 
HG.(Ed) Profiles of Drug Substances, Excipients 
and Related Methodology. 2017, Cambridge MA, 
Elsevier, 125-192 ISBN 978-0-12-804784-2. 
8. Dash RN, Mohammed H, Humaira T, Ramesh D. 
Design, optimization and evaluation of glipizide 
solid self-nanoemulsifying drug delivery for 
enhanced solubility and dissolution. Saudi Pharm J, 
2015; 23: 528–540. DOI:10.1016/j.jsps.2015.01.024. 
9. Nipun TS, Ashraful Islam SM. SEDDS of 
gliclazide: Preparation and characterization by in-
vitro, ex-vivo and in-vivo techniques. Saudi Pharm 
J, 2014; 22: 343–348. 
https://doi.org/10.1016/j.jsps.2013.06.001. 
10. Wilczewska AZ, Niemirowicz K, Markiewicz HH, 
Car H. Nanoparticles as Drug Delivery Systems. 
Pharmacol Rep, 2012; 64(5): 1020-1037. 
11. Martin JE, Snezhko A. Driving self-assembly and 
emergent dynamics in colloidal suspensions by time-
dependent magnetic fields Rep Prog Phys, 2013; 
76(12): published on line DOI: 10.1088/0034-
4885/76/12/126601/meta. 
12. Bhattacharya S, Prajapati B. Formulation Approach 
of Self Emulsifying Drug Delivery System. Int J 
Pharm Formulat Anal, 2015; 6(1): 1-6 Available at: 
https://www.researchgate.net/publication/291103056
_Formulation_Approach_of_Self_Emulsifying_Dru
g_Delivery_System_Formulation_Approach_of_Sel
f_Emulsifying_Drug_Delivery_System [Accessed 
14 Aug. 2017]. 
13. Gupta S, Sandip C, Sawant KK. Self-
nanoemulsifying drug delivery system for adefovir 
dipivoxil: Design, characterization, in vitro and ex 
vivo evaluation Colloid Surface A, 2011; 392(1): 
145-155. DOI: 
https://doi.org/10.1016/j.colsurfa.2011.09.048. 
14. Senapati PC, Sahoo SK, Sahu AN. Mixed surfactant 
based (SNEDDS) self-nano-emulsifying drug 
delivery system presenting efavirenz for 
enhancement of oral bioavailability. Biomed 
Pharmacother, 2016; 80: 42–51. 
https://doi.org/10.1016/j.biopha.2016.02.039 
15. Gursoy RN, Benita S. Self-emulsifying drug 
delivery systems (SEDDS) for improved oral 
delivery of lipophilic drugs. Biomed Pharmacother, 
2004; 58: 173–182. DOI: 
10.1016/j.biopha.2004.02.001. 
16. Constantinides PP, Lipid microemulsions for 
improving drug dissolution and oral absorption: 
physical and biopharmaceutical aspects. Pharm Res, 
1995; 12: 1561–1572. 
17. Reiss H. Entropy-induced dispersion of bulk liquids. 
J Colloid Interface Sci, 1975; 53: 61–70. 
https://doi.org/10.1016/0021-9797(75)90035-1. 
18. Singh B, Khurana L, Bandyopadhyay S, Kapil R, 
Katare OOP. Development of optimized self-nano-
emulsifying drug delivery systems (SNEDDS) of 
carvedilol with enhanced bioavailability potential. 
Drug Deliv, 2011; 18(8): 599-612. 
DOI:10.3109/10717544.2011.604686. 
19. Chiesa M, Garg J, Kang YT, Chen G. Thermal 
conductivity and viscosity of water-in-oil 
nanoemulsions. Colloid Surface A, 2008; 326(1-2): 
67-72. DOI: 10.1016/j.colsurfa.2008.05.028. 
20. Niederquell A, Kuentz M. Proposal of stability 
categories for nano-dispersions obtained from 
pharmaceutical self-emulsifying formulations. Int J 
Pharmaceut, 2013; 446(1-2): 70-80. DOI: 
10.1016/j.ijpharm.2013.02.005. 
21. Salager JL,.Forgiarini A, Márquez L, Peña A, 
Pizzino A, Rodriguez MP, Rondón-González M. 
Using emulsion inversion in industrial processes. 
Adv Colloid Interface Sci, 2003; 108-109: 259-272. 
DOI:10.1016/j.cis.2003.10.008. 
22. Tadros T, Izquierdo P, Esquena J, Solans C. 
Formation and stability of nano-emulsions. Adv 
Colloid Interface Sci, 2004; 108-109, 303-318. 
DOI:10.1016/j.cis.2003.10.023. 
23. Usón, N.,. Garcia, M.J., Solans C. Formation of 
water-in-oil (W/O) nano-emulsions in a water/mixed 
non-ionic surfactant/oil systems prepared by a low-
energy emulsification method Colloid Surface A, 
2004; 250(1–3): 415-421. 
https://doi.org/10.1016/j.colsurfa.2004.03.039. 
